Pfizer (PFE 1.87%) is going through a rough patch. Slumping sales of its COVID-19 products have caused the drugmaker's shares to plunge by over 40.7% year to date. But it isn't all doom and gloom at the global pharma giant. Johnson & Johnson (JNJ -0.71%) is another deeply undervalued healthcare stock that screens as a top buy for income investors right now. The company's shares have dropped by over 13% year to date in response to litigation concerns, but its underlying business is humming along just fine.
Source: Motley Fool
Related Articles:
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.